These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 16087945)

  • 1. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B; Semiglazov V; Pawlicki M; Pienkowski T; Tjulandin S; Manikhas G; Makhson A; Roth A; Dodwell D; Baselga J; Biakhov M; Valuckas K; Voznyi E; Liu X; Vercammen E
    J Clin Oncol; 2005 Sep; 23(25):5960-72. PubMed ID: 16087945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
    Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
    J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J; Couture F; Young S; McWatters KL; Lau CY
    J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    Grote T; Yeilding AL; Castillo R; Butler D; Fishkin E; Henry DH; DeLeo M; Fink K; Sullivan DJ
    J Clin Oncol; 2005 Dec; 23(36):9377-86. PubMed ID: 16361638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
    J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
    Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.
    Steensma DP; Molina R; Sloan JA; Nikcevich DA; Schaefer PL; Rowland KM; Dentchev T; Novotny PJ; Tschetter LK; Alberts SR; Hogan TF; Law A; Loprinzi CL
    J Clin Oncol; 2006 Mar; 24(7):1079-89. PubMed ID: 16505427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
    Biesma B; van de Werf PR; Melissant CF; Brok RG
    Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
    Rades D; Tribius S; Yekebas EF; Bahrehmand R; Wildfang I; Kilic E; Muellerleile U; Gross E; Schild SE; Alberti W
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):459-65. PubMed ID: 16584851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D; George MJ; Harrison LB
    Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
    J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.